Bo Cen
- Oncology top 5%
- Peptidase Inhibition and Analysis 4
- Chemokine receptors and signaling 2
- Cancer Immunotherapy and Biomarkers 2
- Immunology top 10%
- Immune Cell Function and Interaction 2
- Cancer Research top 10%
- Molecular Biology top 10%
- Receptor Mechanisms and Signaling 4
- Pharmacological Receptor Mechanisms and Effects 2
- Immunology and Allergy top 10%
-
- Cancer Mechanisms and Therapy 7
-
- Neuropeptides and Animal Physiology 3
- Co-authors
- Ron PrywesJie WeiDingzhi WangRaymond N. DuBoisHaiyan SunZhigui MaRebecca C. BurgessJohann Hitzler
- Cited by
- OncologyImmunologyCancer Research
- Partner nations
- United StatesChinaCanada
In The Last Decade
Bo Cen
22 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 86
- Oncology 497
- Immunology 331
- Cancer Research 181
- Molecular Biology 822
- Immunology and Allergy 66
Countries citing papers authored by Bo Cen
This map shows the geographic impact of Bo Cen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Cen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Cen more than expected).
Fields of papers citing papers by Bo Cen
This network shows the impact of papers produced by Bo Cen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Cen. The network helps show where Bo Cen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bo Cen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2021 | 33 | |
| 3 | 2019 | 50 | |
| 4 | 2017 | 274 | |
| 5 | 2017 | 21 | |
| 6 | 2016 | 14 | |
| 7 | 2015 | 21 | |
| 8 | 2014 | 21 | |
| 9 | 2013 | 52 | |
| 10 | 2010 | 26 | |
| 11 | 2008 | 24 | |
| 12 | 2008 | 25 | |
| 13 | 2008 | 35 | |
| 14 | 2004 | 136 | |
| 15 | 2001 | 43 | |
| 16 | 2001 | 6 | |
| 17 | 2001 | 61 | |
| 18 | 2000 | 183 | |
| 19 | 1997 | 3 | |
| 20 | 1997 | 3 |
About Bo Cen
Bo Cen is a scholar working on Physiology, Pathology and Forensic Medicine, Oncology, Molecular Biology and Immunology, having authored 22 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer Mechanisms and Therapy (7 papers), Peptidase Inhibition and Analysis (4 papers), Receptor Mechanisms and Signaling (4 papers), Neuropeptides and Animal Physiology (3 papers), Pharmacological Receptor Mechanisms and Effects (2 papers), Chemokine receptors and signaling (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Oncology (497 citations), Immunology (331 citations), Cancer Research (181 citations), Molecular Biology (822 citations) and Immunology and Allergy (66 citations). Bo Cen has collaborated with scholars based in United States, China and Canada. Frequent co-authors include Ron Prywes, Jie Wei, Dingzhi Wang, Raymond N. DuBois, Haiyan Sun, Zhigui Ma, Rebecca C. Burgess, Johann Hitzler, Stephan W. Morris and Andrew S. Kraft. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, IUBMB Life, Molecular and Cellular Biology and Molecular Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.